Which agents are commonly associated with cytokine release syndrome?

Cytokine release syndrome (CRS) is a potentially severe side effect that arises from certain immunotherapeutic agents. The correct choice identifies agents like interferons, interleukins, monoclonal antibodies, and CAR-T cells as those commonly associated with CRS.

These agents work by stimulating the immune system to attack tumors or infected cells, which can lead to a significant release of cytokines—proteins that are crucial for cell signaling in the immune response. When these cytokines are released in large quantities, they can trigger symptoms ranging from mild flu-like symptoms to severe reactions, including fever, rash, and potential organ dysfunction.

This understanding highlights the nature of the immunotherapies involved and their mechanism of action in provoking an immune response, which in turn leads to the occurrence of CRS. The use of these specific agents necessitates careful monitoring and possible premedication strategies to manage the risk of CRS effectively.